A pharmaceutical industry executive collapsed unexpectedly in the Oval Office today during a press briefing. The incident occurred while he was positioned behind the US president during an event where the Trump administration was introducing a new agreement for weight-loss medications, causing his knees to give way suddenly.
Upon witnessing the collapse, administration officials and representatives from pharmaceutical companies rushed to assist the individual to prevent him from falling. White House Press Secretary Karoline Leavitt disclosed that during the ‘Most Favored Nations Oval Office Announcement’, a representative from one of the companies had fainted.
Leavitt mentioned that medical personnel on-site promptly responded to the situation, confirming that the individual was ultimately fine. She reassured that the press conference would recommence shortly.
A statement released stated: “During the Most Favored Nations Oval Office Announcement, a representative from one of the companies fainted. The White House Medical Unit acted swiftly, and the individual is in good condition. The Press Conference will resume shortly.”
Following the incident, reporters were escorted out of the Oval Office as cabinet members attended to the collapsed individual and raised his legs. The reason behind his collapse remains unknown.
The press conference featured executives from pharmaceutical giants Novo Nordisk and Eli Lilly standing alongside the Trump administration to introduce a groundbreaking agreement that could have a significant impact on the healthcare industry. Under the initiative, the manufacturers of Ozempic, Wegovy, and Zepbound will offer their highly sought-after treatments directly to the public through TrumpRx, a new government website set to launch next year.
In a victory for patients, the companies announced that an oral version of the medications could potentially cost $149 (£113) per month following approval from the Food and Drug Administration. Additionally, individuals on Medicare or Medicaid dealing with diabetes and other qualifying conditions will benefit from a reduced price of $245 (£186) per month for injectable versions.
